Response to: Tocilizumab, neuromyelitis optica (NMO), and multiple sclerosis

被引：3

作者：

Beauchemina, Philippe ^{[1
,2
]}

Carruthers, Robert ^{[2
]}

机构：

[1] Univ Laval, Dept Sci Neurol, CHU Quebec, Hop Enfant Jesus, Quebec City, PQ, Canada

[2] Univ British Columbia, Dept Neurol, UBC Hosp, MS Clin, 2215 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada

来源：

MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷 / 14期

关键词：

D O I：

10.1177/1352458516643398

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：1892 / 1893

页数：2

共 3 条

[1] Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study [J].

Araki, Manabu ;

Matsuoka, Takako ;

Miyamoto, Katsuichi ;

Kusunoki, Susumu ;

Okamoto, Tomoko ;

Murata, Miho ;

Miyake, Sachiko ;

Aranami, Toshimasa ;

Yamamura, Takashi .

NEUROLOGY, 2014, 82 (15) :1302-1306

[2] Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab [J].

Araki, Manabu ;

Aranami, Toshimasa ;

Matsuoka, Takako ;

Nakamura, Masakazu ;

Miyake, Sachiko ;

Yamamura, Takashi .

MODERN RHEUMATOLOGY, 2013, 23 (04) :827-831

[3] Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy [J].

Ayzenberg, Ilya ;

Kleiter, Ingo ;

Schroeder, Alexandra ;

Hellwig, Kerstin ;

Chan, Andrew ;

Yamamura, Takashi ;

Gold, Ralf .

JAMA NEUROLOGY, 2013, 70 (03) :394-397

← 1 →